Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Wednesday

Posted by Stanley Muller on Oct 28th, 2026

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) is expected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Viridian Therapeutics to announce earnings of ($1.02) per share and revenue of $4.72 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.06 million. On average, analysts expect Viridian Therapeutics to post ($4.07) EPS for the current fiscal year and ($2.43) EPS for the next fiscal year.

Viridian Therapeutics Price Performance

Shares of VRDN stock opened at $24.09 on Wednesday. The firm has a market cap of $2.73 billion, a P/E ratio of -7.15 and a beta of 1.11. Viridian Therapeutics has a 1-year low of $13.18 and a 1-year high of $34.29. The firm’s 50-day simple moving average is $21.65 and its 200-day simple moving average is $22.05.

Insider Activity

In related news, insider Jennifer Tousignant sold 14,212 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total value of $348,194.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on VRDN shares. Wall Street Zen lowered shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Weiss Ratings upgraded shares of Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 14th. Royal Bank Of Canada lifted their price target on shares of Viridian Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Tuesday, September 22nd. Wedbush boosted their price objective on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $39.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, June 30th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.92.

Check Out Our Latest Research Report on VRDN

Viridian Therapeutics Company Profile

(Get Free Report)

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.